EGFR and non-small cell lung carcinoma: reported a 78-year-old woman presenting with mild exertional dyspnea 3 weeks after starting osimertinib for the treatment of EGFR T790M-positive NSCLC, and she was diagnosed with congestive heart failure caused by the osimertinib (20).